News | June 07, 2021
Glenmark receives ANDA approval for theophylline extended-release tablets
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
This marks Glenmark's first synthetic decapeptide injectable approval
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated
